AbbVie's CEO, Robert Michael, has voiced support for potential new U.S. trade measures aimed at foreign drug pricing. His comments came as reports emerged that the Trump administration is considering a probe under Section 301 of the Trade Act of 1974 to address disparities between U.S. and international drug prices. This could lead to significant tariffs on pharmaceuticals from other countries. Michael stated that pharmaceutical companies need a "partnership with the administration through trade negotiations to address these unfair practices." This stance suggests that major industry players like AbbVie may be open to government intervention to alter the global pricing landscape, which could have substantial financial implications for the company and the broader sector. While there has been no official announcement from the White House, the reports and the CEO's commentary introduce a new layer of regulatory and trade-related uncertainty for pharmaceutical companies. The potential for tariffs could reshape how drugs are priced and sold internationally. No specific market reaction for AbbVie's stock was detailed in the immediate reports.